{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:14:21Z","timestamp":1787004861712,"version":"build-2736575974"},"reference-count":27,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Was ist neu?<\/jats:title>\n                  <jats:p>Diagnostik Bei Verdacht auf tiefe Beinvenenthrombose ist die ven\u00f6se Duplexsonografie Methode der 1. Wahl. Bei nicht zeitnah verf\u00fcgbarem qualifiziertem Ultraschall k\u00f6nnen bei niedriger klinischer Wahrscheinlichkeit D-Dimere und limitierte Point-of-Care-Ultraschallprotokolle zur prim\u00e4ren Entscheidungsfindung beitragen. Bei Verdacht auf eine Lungenembolie sollte eine D-Dimer-Testung dagegen nur bei niedriger bzw. mittlerer klinischer Wahrscheinlichkeit erfolgen, da bei normwertigen D-Dimeren eine Lungenembolie (LE) als ausgeschlossen gilt.<\/jats:p>\n                  <jats:p>Antikoagulanzien-Therapie Ein DOAK-basiertes Therapieregime ist sowohl f\u00fcr die Therapie der akuten ven\u00f6sen Thromboembolie (VTE) als auch f\u00fcr die medikament\u00f6se Sekund\u00e4rprophylaxe gegen\u00fcber einer Therapie mit Vitamin-K-Antagonisten zu bevorzugen. Die Antikoagulation mit DOAK ist unproblematisch bis zu einem K\u00f6rpergewicht (KG) von 120kg bzw. einem Body-Mass-Index (BMI) von 40kg\/m\u00b2. F\u00fcr Apixaban und Rivaroxaban werden keine Gewichtsbeschr\u00e4nkungen mehr empfohlen, allerdings ist die Bestimmung der DOAK-Tal- und Spitzenspiegel bei Menschen mit extremer Adipositas und Patienten nach bariatrischer Chirurgie empfehlenswert.<\/jats:p>\n                  <jats:p>Assoziationen mit anderen Erkrankungen Bei tumorassoziierter VTE sind die direkten Faktor-Xa-Inhibitoren in vielen F\u00e4llen eine gute und sichere Alternative zu NMH (niedermolekularem Heparin); die Therapieadh\u00e4renz zu einer oralen Therapie ist zudem h\u00f6her.<\/jats:p>\n                  <jats:p>Nachsorge und Evaluation Eine aussagekr\u00e4ftige Erstdokumentation und eine strukturierte Nachsorge nach TBVT (tiefer Beinvenenthrombose) und Lungenembolie (LE) sind wichtig, um am Ende der Therapiephase eine individualisierte Nutzen-Risiko-Abw\u00e4gung hinsichtlich einer fortgef\u00fchrten medikament\u00f6sen Sekund\u00e4rprophylaxe treffen zu k\u00f6nnen, und die Patienten auf das Vorliegen von Folgesch\u00e4den \u2013 wie das postthrombotische Syndrom (PTS) und eine chronische thromboembolische pulmonale Hypertonie (CTEPH) \u2013 zu screenen.<\/jats:p>","DOI":"10.1055\/a-2128-0005","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T19:29:48Z","timestamp":1709062188000},"page":"274-282","source":"Crossref","is-referenced-by-count":4,"title":["Ven\u00f6se Thromboembolie \u2013 was ist neu in der aktualisierten AWMF-Leitlinie?"],"prefix":"10.1055","volume":"149","author":[{"given":"Birgit","family":"Linnemann","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Kardiologie, Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja Sibylle","family":"M\u00fchlberg","sequence":"additional","affiliation":[{"name":"Klinik & Poliklinik f\u00fcr Angiologie, Universit\u00e4tsklinikum Leipzig: Universitatsklinikum Leipzig, Leipzig, GERMANY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klamroth","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Inneren Medizin - Angiologie und H\u00e4mostaseologie, Vivantes Klinikum im Friedrichshain, Berlin,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"I4","DOI":"10.1161\/01.CIR.0000078468.11849.66","article-title":"The epidemiology of venous thromboembolism","volume":"107","author":"RH White","year":"2003","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global Burden of Thrombosis: Epidemiologic Aspects","volume":"118","author":"AM Wendelboe","year":"2016","journal-title":"Circ Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jvsv.2012.07.003","article-title":"Post-thrombotic syndrome 3 years after deep venous thrombosis in the Thrombosis and Pulmonary Embolism in Out-Patients (TULIPA) PLUS Registry","volume":"1","author":"V Hach-Wunderle","year":"2013","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1182\/blood-2018-01-785956","article-title":"How I treat the postthrombotic syndrome","volume":"131","author":"A Rabinovich","year":"2018","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01792-2016","article-title":"Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature","volume":"49","author":"YM Ende-Verhaar","year":"2017","journal-title":"Eur Respir J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/14017431.2016.1185532","article-title":"Characteristics and survival of adult Swedish PAH and CTEPH patients 2000\u20132014","volume":"50","author":"G R\u00e5degran","year":"2016","journal-title":"Scand Cardiovasc J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1024\/0301-1526\/a001089","article-title":"Diagnostics and therapy of venous thrombosis and pulmonary embolism. AWMF-S2k-guideline","volume":"52","author":"B Linnemann","year":"2023","journal-title":"Vasa"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","author":"T van der Hulle","year":"2014","journal-title":"J Thromb Haemost"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"N van Es","year":"2014","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH","volume":"14","author":"K Martin","year":"2016","journal-title":"J Thromb Haemost"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"KA Martin","year":"2021","journal-title":"J Thromb Haemost"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants","volume":"118","author":"RC Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)","volume":"36","author":"AM Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"RD McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"GE Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"ref17","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"FI Mulder","year":"2020","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.1016\/S0049-3848(14)50028-X","article-title":"Cancer-associated unsuspected pulmonary embolism","volume":"133","author":"N van Es","year":"2014","journal-title":"Thromb Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/jth.12883","article-title":"Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH","volume":"13","author":"M Di Nisio","year":"2015","journal-title":"J Thromb Haemost"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/asheducation-2017.1.121","article-title":"Incidental venous thromboembolism: is anticoagulation indicated?","volume":"2017","author":"M Di Nisio","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.7326\/M21-2981","article-title":"Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation : A Multicenter Prospective Cohort Study","volume":"175","author":"G Le Gal","year":"2022","journal-title":"Ann Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood-2013-04-497545","article-title":"Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism","volume":"122","author":"den Exter PL","year":"2013","journal-title":"Blood"},{"issue":"01","key":"ref23","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"M Humbert","year":"2022","journal-title":"Eur Respir J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.7326\/0003-4819-150-9-200905050-00003","article-title":"Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial","volume":"150","author":"P Prandoni","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis","volume":"174","author":"F Khan","year":"2021","journal-title":"Ann Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism","volume":"376","author":"JI Weitz","year":"2017","journal-title":"N Engl J Med"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2128-0005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T09:13:04Z","timestamp":1730797984000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2128-0005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":27,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2024,2,27]]},"published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2128-0005","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]}}}